drugset / Trial / NCT05557240
Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the safety and tolerability, feasibility of the NeoPep Vaccine in newly diagnosed glioblastoma (GB) patients.
Timeline
- Start
- 2022-09-13
- Primary completion
- 2024-02-12
- Completion
- 2025-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NeoPep Vaccine1 | Vaccine | 400 ug | — |
| Subject | NeoPep Vaccine2 | Vaccine | 400 ug | — |
| Background | Hiltonol | Other / unclassified | 500 ug | — |